个人中心 - 老虎社区

TAN PS

IP属地：未知

帖子 · 20帖子 · 20
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- TAN PSTAN PS
  ·2022-01-21
  OK👌
  3 COVID Stocks That Will Make Billions in 2022
  These three COVID-19 stocks could rake in a tremendous amount of cash this year.
  3 COVID Stocks That Will Make Billions in 2022
  2,784 评论
  1
  分享
  举报
- TAN PSTAN PS
  ·2022-01-21
  OK👌
  Stocks rise as Wall Street shakes off red hot inflation report
  Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high
  Stocks rise as Wall Street shakes off red hot inflation report
  1,917 评论
  1
  分享
  举报
- TAN PSTAN PS
  ·2022-01-19
  Ok👌
  外媒头条：一次加息50个基点！市场预期越发激进
  全球财经媒体昨夜今晨共同关注的头条新闻主要有：1、货币市场预计美联储或一次升息50基点将是2020年以来最大动作2、微软发起其史上最大规模收购以近690亿美元收购动视暴雪3、贝莱德CEO：美联储“
  外媒头条：一次加息50个基点！市场预期越发激进
  4,209 评论
  点赞
  分享
  举报
- TAN PSTAN PS
  ·2021-12-28
  Ok,goood
  2,014 评论
  点赞
  分享
  举报
- TAN PSTAN PS
  ·2021-12-27
  Ok, great idea
  2,587 评论
  点赞
  分享
  举报
- TAN PSTAN PS
  ·2021-12-27
  Okokok☺️☺️☺️
  2,005 评论
  点赞
  分享
  举报
- TAN PSTAN PS
  ·2021-12-26
  Ok
  非常抱歉，此主贴已删除
  2,269 1
  4
  分享
  举报
- TAN PSTAN PS
  ·2021-12-25
  Ok
  非常抱歉，此主贴已删除
  2,251 1
  8
  分享
  举报
- TAN PSTAN PS
  ·2021-12-24
  Okokok good idea
  2,193 评论
  1
  分享
  举报
- TAN PSTAN PS
  ·2021-12-24
  Ok
  非常抱歉，此主贴已删除
  1,696 评论
  5
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582126034262927","uuid":"3582126034262927","gmtCreate":1619032504746,"gmtModify":1642212623813,"name":"TAN PS","pinyin":"tanpstanps","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":61,"tweetSize":20,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":630345015,"gmtCreate":1642725433815,"gmtModify":1642725441780,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582126034262927","authorIdStr":"3582126034262927"},"themes":[],"htmlText":"OK👌","listText":"OK👌","text":"OK👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630345015","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://www.laohu8.com/m/news/1134509683?lang=&edition=full","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<html><head></head><body><p>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><b>A safe harbor in stormy weather</b></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><b>The antibody market all to itself</b></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-08 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","VIR":"Vir Biotechnology, Inc."},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax:  $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"VIR":0.9}},"isVote":1,"tweetType":1,"viewCount":2784,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630342483,"gmtCreate":1642725393521,"gmtModify":1642725393632,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582126034262927","authorIdStr":"3582126034262927"},"themes":[],"htmlText":"OK👌","listText":"OK👌","text":"OK👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630342483","repostId":"1138592368","repostType":4,"repost":{"id":"1138592368","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641997842,"share":"https://www.laohu8.com/m/news/1138592368?lang=&edition=full","pubTime":"2022-01-12 22:30","market":"us","language":"en","title":"Stocks rise as Wall Street shakes off red hot inflation report","url":"https://stock-news.laohu8.com/highlight/detail?id=1138592368","media":"Tiger Newspress","summary":"Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high","content":"<html><head></head><body><p>Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high rate of price increases across the recovering economy. Still, this came a day following remarks from Federal Reserve Chair Jerome Powell reasserting that the central bank would step in as needed to rein in rising prices.</p><p>The Bureau of Labor Statistics&#39; December Consumer Price Index (CPI)showed prices rose at a 7.0% year-over-year rate at the end of 2021, marking the fastest increase since 1982. This matched consensus estimates, based on Bloomberg data, and accelerated from November&#39;s already elevated 6.8% increase. On a month-over-month basis, consumer prices rose 0.5%, or slightly more than the 0.4% rise expected, to mark an eighteenth consecutive month of prices increases.</p><p>Excluding food and energy prices, the so-called core measure of consumer prices rose 5.5% in December over last year, coming in at the fastest rate since 1991.</p><p>Wednesday&#39;s market moves came following a rebound rally on Tuesday, with markets at least temporarily finding relief in assurances from Federal Reserve Chair Jerome Powell that the central bank would step in as necessary to ease rising prices. InPowell&#39;s renomination hearing before the Senate Banking Committee, the central bank leader reiterated that the Fed would use its policy tools to bring down inflation.</p><p>“If we see inflation persisting at high levels, longer than expected, if we have to raise interest rates more over time, then we will,” Powell said during the hearing.</p><p>The central bankpreviously telegraphed it was eyeing three interest rate hikesthis year to bring benchmark rates up from their current near-zero levels. However, some topWall Street firms have predictedthe Fed will raise rates four times given the current inflationary backdrop.</p><p>But though Powell doubled down on the Fed&#39;s goal of curbing inflation and using interest rate hikes as a tool to achieve this, he revealed little further about the Fed&#39;s plan to begin shrinking its nearly $9 trillion balance sheet. The Fed&#39;s December meeting minutes last week suggested central bank officials were beginning to discuss drawing down the Fed&#39;s balance sheet after nearly two years of asset purchases to help support markets during the pandemic. Powell did reiterate in his hearing he expected the balance sheet runoff process would begin this year.</p><p>&#34;I think the biggest comment on most investors&#39; minds that we talk to around the world would be a &#39;policy mistake&#39; that the Fed might be too aggressive,&#34; Brian Belski, BMO Capital Markets chief investment strategist,told Yahoo Finance Live on Tuesday.&#34;Mr. Powell basically came out today and said this is going to be a process ... with respect to how long this is going to take, and I think that&#39;s what&#39;s calming investors.&#34;</p><p>Though prospects of higher borrowing costs and tighter financial conditions have stirred up volatility in U.S. equities and tech stocks especially in recent sessions, Tuesday&#39;s session saw a reversal, with the tech-heavy Nasdaq Composite sharply outperforming.</p><p>&#34;The issue with tech, I would argue, is not so much one of a little extra duration exposure because growth is further away, but it&#39;s simply one of valuation,&#34; Simeon Hyman, ProShares Global Investment Strategist,told Yahoo Finance Live on Tuesday.&#34;And indeed those top-heavy, largest-cap tech stocks perhaps just were a little bit expensive going into the end of last year and the beginning of 2022. But don&#39;t completely rule out good growth stories because that is the biggest defense against inflation. It is the growth of earnings and dividends.&#34;</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks rise as Wall Street shakes off red hot inflation report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks rise as Wall Street shakes off red hot inflation report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-12 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high rate of price increases across the recovering economy. Still, this came a day following remarks from Federal Reserve Chair Jerome Powell reasserting that the central bank would step in as needed to rein in rising prices.</p><p>The Bureau of Labor Statistics&#39; December Consumer Price Index (CPI)showed prices rose at a 7.0% year-over-year rate at the end of 2021, marking the fastest increase since 1982. This matched consensus estimates, based on Bloomberg data, and accelerated from November&#39;s already elevated 6.8% increase. On a month-over-month basis, consumer prices rose 0.5%, or slightly more than the 0.4% rise expected, to mark an eighteenth consecutive month of prices increases.</p><p>Excluding food and energy prices, the so-called core measure of consumer prices rose 5.5% in December over last year, coming in at the fastest rate since 1991.</p><p>Wednesday&#39;s market moves came following a rebound rally on Tuesday, with markets at least temporarily finding relief in assurances from Federal Reserve Chair Jerome Powell that the central bank would step in as necessary to ease rising prices. InPowell&#39;s renomination hearing before the Senate Banking Committee, the central bank leader reiterated that the Fed would use its policy tools to bring down inflation.</p><p>“If we see inflation persisting at high levels, longer than expected, if we have to raise interest rates more over time, then we will,” Powell said during the hearing.</p><p>The central bankpreviously telegraphed it was eyeing three interest rate hikesthis year to bring benchmark rates up from their current near-zero levels. However, some topWall Street firms have predictedthe Fed will raise rates four times given the current inflationary backdrop.</p><p>But though Powell doubled down on the Fed&#39;s goal of curbing inflation and using interest rate hikes as a tool to achieve this, he revealed little further about the Fed&#39;s plan to begin shrinking its nearly $9 trillion balance sheet. The Fed&#39;s December meeting minutes last week suggested central bank officials were beginning to discuss drawing down the Fed&#39;s balance sheet after nearly two years of asset purchases to help support markets during the pandemic. Powell did reiterate in his hearing he expected the balance sheet runoff process would begin this year.</p><p>&#34;I think the biggest comment on most investors&#39; minds that we talk to around the world would be a &#39;policy mistake&#39; that the Fed might be too aggressive,&#34; Brian Belski, BMO Capital Markets chief investment strategist,told Yahoo Finance Live on Tuesday.&#34;Mr. Powell basically came out today and said this is going to be a process ... with respect to how long this is going to take, and I think that&#39;s what&#39;s calming investors.&#34;</p><p>Though prospects of higher borrowing costs and tighter financial conditions have stirred up volatility in U.S. equities and tech stocks especially in recent sessions, Tuesday&#39;s session saw a reversal, with the tech-heavy Nasdaq Composite sharply outperforming.</p><p>&#34;The issue with tech, I would argue, is not so much one of a little extra duration exposure because growth is further away, but it&#39;s simply one of valuation,&#34; Simeon Hyman, ProShares Global Investment Strategist,told Yahoo Finance Live on Tuesday.&#34;And indeed those top-heavy, largest-cap tech stocks perhaps just were a little bit expensive going into the end of last year and the beginning of 2022. But don&#39;t completely rule out good growth stories because that is the biggest defense against inflation. It is the growth of earnings and dividends.&#34;</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138592368","content_text":"Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high rate of price increases across the recovering economy. Still, this came a day following remarks from Federal Reserve Chair Jerome Powell reasserting that the central bank would step in as needed to rein in rising prices.The Bureau of Labor Statistics' December Consumer Price Index (CPI)showed prices rose at a 7.0% year-over-year rate at the end of 2021, marking the fastest increase since 1982. This matched consensus estimates, based on Bloomberg data, and accelerated from November's already elevated 6.8% increase. On a month-over-month basis, consumer prices rose 0.5%, or slightly more than the 0.4% rise expected, to mark an eighteenth consecutive month of prices increases.Excluding food and energy prices, the so-called core measure of consumer prices rose 5.5% in December over last year, coming in at the fastest rate since 1991.Wednesday's market moves came following a rebound rally on Tuesday, with markets at least temporarily finding relief in assurances from Federal Reserve Chair Jerome Powell that the central bank would step in as necessary to ease rising prices. InPowell's renomination hearing before the Senate Banking Committee, the central bank leader reiterated that the Fed would use its policy tools to bring down inflation.“If we see inflation persisting at high levels, longer than expected, if we have to raise interest rates more over time, then we will,” Powell said during the hearing.The central bankpreviously telegraphed it was eyeing three interest rate hikesthis year to bring benchmark rates up from their current near-zero levels. However, some topWall Street firms have predictedthe Fed will raise rates four times given the current inflationary backdrop.But though Powell doubled down on the Fed's goal of curbing inflation and using interest rate hikes as a tool to achieve this, he revealed little further about the Fed's plan to begin shrinking its nearly $9 trillion balance sheet. The Fed's December meeting minutes last week suggested central bank officials were beginning to discuss drawing down the Fed's balance sheet after nearly two years of asset purchases to help support markets during the pandemic. Powell did reiterate in his hearing he expected the balance sheet runoff process would begin this year.\"I think the biggest comment on most investors' minds that we talk to around the world would be a 'policy mistake' that the Fed might be too aggressive,\" Brian Belski, BMO Capital Markets chief investment strategist,told Yahoo Finance Live on Tuesday.\"Mr. Powell basically came out today and said this is going to be a process ... with respect to how long this is going to take, and I think that's what's calming investors.\"Though prospects of higher borrowing costs and tighter financial conditions have stirred up volatility in U.S. equities and tech stocks especially in recent sessions, Tuesday's session saw a reversal, with the tech-heavy Nasdaq Composite sharply outperforming.\"The issue with tech, I would argue, is not so much one of a little extra duration exposure because growth is further away, but it's simply one of valuation,\" Simeon Hyman, ProShares Global Investment Strategist,told Yahoo Finance Live on Tuesday.\"And indeed those top-heavy, largest-cap tech stocks perhaps just were a little bit expensive going into the end of last year and the beginning of 2022. But don't completely rule out good growth stories because that is the biggest defense against inflation. It is the growth of earnings and dividends.\"","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":1917,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697404839,"gmtCreate":1642551869823,"gmtModify":1642551870152,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582126034262927","authorIdStr":"3582126034262927"},"themes":[],"htmlText":"Ok👌","listText":"Ok👌","text":"Ok👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697404839","repostId":"2204841800","repostType":2,"repost":{"id":"2204841800","kind":"news","pubTimestamp":1642541820,"share":"https://www.laohu8.com/m/news/2204841800?lang=&edition=full","pubTime":"2022-01-19 05:37","market":"sh","language":"zh","title":"外媒头条：一次加息50个基点！市场预期越发激进","url":"https://stock-news.laohu8.com/highlight/detail?id=2204841800","media":"新浪财经","summary":"全球财经媒体昨夜今晨共同关注的头条新闻主要有：1、货币市场预计美联储或一次升息50基点 将是2020年以来最大动作2、微软发起其史上最大规模收购 以近690亿美元收购动视暴雪3、贝莱德CEO：美联储“","content":"<html><head></head><body><p><b>全球财经媒体昨夜今晨共同关注的头条新闻主要有：</b></p><blockquote><b>1、货币市场预计美联储或一次升息50基点 将是2020年以来最大动作</b></blockquote><blockquote><b>2、<a href=\"https://laohu8.com/S/MSFT\">微软</a>发起其史上最大规模收购 以近690亿美元收购<a href=\"https://laohu8.com/S/ATVI\">动视暴雪</a></b></blockquote><blockquote><b>3、<a href=\"https://laohu8.com/S/BLK\">贝莱德</a>CEO：美联储“激进”立场或导致收益率曲线趋平</b></blockquote><blockquote><b>4、原油飙升至2014年以来高点 拜登政府称正继续与产油国合作</b></blockquote><blockquote><b>5、研究显示omicron感染浪潮可能降低疫情未来的严重程度</b></blockquote><blockquote><b>6、2021年<a href=\"https://laohu8.com/S/AAPL\">苹果</a>手机占全球智能手机出货量22% 位居第一</b></blockquote><p><img src=\"https://static.tigerbbs.com/698315ff48290ccd4244f61fe7019f2b\" tg-width=\"550\" tg-height=\"369\" referrerpolicy=\"no-referrer\"/></p><p><b>货币市场预计美联储或一次升息50基点 将是2020年以来最大动作</b></p><p>货币市场价格显示，越来越多投资者预期美联储可能逾二十年来首次大规模提高借贷成本。</p><p>虽然加息25个基点仍是最有可能的情形，但掉期市场现在预计3月底前加息幅度将超过25个基点。鉴于本月政策会议预计不会有任何行动，这表明交易员至少正在考虑3月加息50个基点的可能性。自2000年5月以来， 美联储还从没有一口气加息这么多过。</p><p>近日来围绕美联储更大幅加息的猜测升温可能加剧了周二美国国债跌势。 <a href=\"https://laohu8.com/S/JPM\">摩根大通</a>首席执行官杰米·戴蒙上周警告美联储收紧政策可能不会像一些人预期的那样“和风细雨”，亿万富翁投资者Bill Ackman表示美联储应该在3月加息50个基点，以重建公信力。</p><p>CFTC最新持仓数据显示，对冲基金将净欧洲美元空头头寸提高至2018年12月以来最大水平，投机者对10年期国债期货的看空程度也达到2020年2月以来最高。</p><p><img src=\"https://static.tigerbbs.com/d7cad28562d81d8fed2fe8d732aa7112\" tg-width=\"550\" tg-height=\"296\" referrerpolicy=\"no-referrer\"/></p><p><b><a href=\"https://laohu8.com/S/MSFT\">微软</a>发起其史上最大规模收购 以近690亿美元收购<a href=\"https://laohu8.com/S/ATVI\">动视暴雪</a></b></p><p>微软宣布以687亿美元收购动视暴雪，促成视频游戏领域的两大巨头强强联合。</p><p>作为微软有史以来进行的最大一笔收购，该交易对这家美国最大游戏发行商之一的收购价为每股95美元现金。微软称，动视暴雪首席执行官Bobby Kotick将继续担任当前职位。交易完成后，动视暴雪业务将汇报给微软游戏部门负责人Phil Spencer。</p><p>交易完成后，微软将成为按营收计算的全球第三大游戏公司，仅次于<a href=\"https://laohu8.com/S/00700\">腾讯</a>和<a href=\"https://laohu8.com/S/SNE\">索尼</a>。</p><p>将动视暴雪热门游戏收入囊中，将有助于微软扩大其Xbox游戏机内容，提高对<a href=\"https://laohu8.com/S/SONY\">索尼</a>PlayStation的竞争力。动视暴雪与Xbox的合作由来已久。这家发行商最大一款游戏《使命召唤》的成功，很大程度上是得益于微软创新性的在线平台Xbox Live，该平台允许玩家联机进行多人对战。动视暴雪大多数游戏都在Xbox游戏机上发布。</p><p><img src=\"https://static.tigerbbs.com/733e77ab67cbbd3d5818c24cbcb9916a\" tg-width=\"550\" tg-height=\"366\" referrerpolicy=\"no-referrer\"/></p><p><b><a href=\"https://laohu8.com/S/BLK\">贝莱德</a>CEO：美联储“激进”立场或导致收益率曲线趋平</b></p><p>全球最大资产管理公司贝莱德CEO Larry Fink表示，美联储快速调整货币政策以遏制通胀可能会导致美国国债收益率曲线趋于平缓。</p><p>“我认为收益率曲线将会变平，如果美联储非常激进，我甚至可以看到一条负的收益率曲线，”Fink周二表示。</p><p>收益率曲线的形状揭示了投资者对美国经济增长和货币政策的预期。美联储计划早于预期加息的鹰派立场推高了短期利率，使曲线变平。</p><p>分析师通常认为，短期美国国债收益率与较长期美债收益率之差缩小（即收益率曲线趋平），是对经济增长和货币政策不确定性的担忧迹象。负的收益率曲线或曲线倒挂通常预示着经济衰退。</p><p>“收益率曲线的形状将成为决定经济的关键问题，”Fink说。</p><p><img src=\"https://static.tigerbbs.com/894b2f0869773330f31bbaf4cb56d3ec\" tg-width=\"550\" tg-height=\"365\" referrerpolicy=\"no-referrer\"/></p><p><b>原油飙升至2014年以来高点 拜登政府称正继续与产油国合作</b></p><p>油价升至七年高点之际，白宫称拜登政府正在与产油国合作，将确保供应达到足以满足需求的水平。</p><p>美国国家安全委员会发言人Emily Horne周二在一份声明中表示，白宫计划继续在全球经济增长的背景下监控能源价格，必要时会与OPEC+国家举行磋商。</p><p>Horne称，“我们会继续与产油国和消费国合作，这些措施已经对价格产生了实际影响，我们仍然保留可解决能源价格问题的工具” 。</p><p>汽油价格上涨一直是导致拜登任期内通胀飙升的主要因素，白宫千方百计降低汽油成本。油价上涨正在损害拜登的支持率，民主党在11月中期选举中保住两院多数党地位的难度加大。</p><p><img src=\"https://static.tigerbbs.com/504a7eb8073637bdb53e621b0dd905d0\" tg-width=\"550\" tg-height=\"343\" referrerpolicy=\"no-referrer\"/></p><p><b>研究显示omicron感染浪潮可能降低疫情未来的严重程度</b></p><p>南非的研究人员表示，虽然omicron变种病毒引发一轮强烈的新冠疫情浪潮，但却可能会加速大流行病所造成各种干扰的终结，因为感染omicron的症状似乎较轻，并能提供针对德尔塔变种病毒的保护。</p><p>南非一个实验室将去年11月和12月感染omicron的23人作为样本进行的研究显示，虽然先前感染了德尔塔毒株的人可以感染omicron，但感染omicron株的人不会再感染德尔塔。</p><p>尽管omicron的感染力明显高于德尔塔，但包括南非在内的一些国家的医院和死亡率数据似乎表明，它导致的疾病严重程度较低。南非是最早出现omicron感染浪潮的国家。南非卫生研究所Alex Sigal等人的这项研究显示，omicron可以取代德尔塔毒株。</p><p>“这种取代的影响将取决于omicron的致病性是否确实低于德尔塔，”研究人员说。 “如果的确如此，那么Covid-19重症的发生率将降低，疫情对个人和社会的破坏性将会减弱。”</p><p><img src=\"https://static.tigerbbs.com/a45e0699fa17a3da9ad6e88c61dcc813\" tg-width=\"630\" tg-height=\"448\" referrerpolicy=\"no-referrer\"/></p><p><b>2021年<a href=\"https://laohu8.com/S/AAPL\">苹果</a>手机占全球智能手机出货量22% 位居第一</b></p><p>数据研究机构Canalys发布的最新报告显示，得益于iPhone 13的成功，苹果手机在2021年占全球智能手机出货量的22%，坐上全球智能手机市场的头把交椅，<a href=\"https://laohu8.com/S/SMSN.UK\">三星</a>以20%的市场份额紧随其后。此外，小米以12%排名第三，OPPO以9%排名第四，vivo以8%排名前五。</p><p>报告显示，截至2021年底，苹果手机占全球智能手机出货量的22%。Canalys指出，苹果上一次在智能手机市场排名第一是在2020年第四季度。</p><p>Canalys分析师Sanyam Chaurasia在一份声明中表示：“苹果iPhone新旗舰机在中国市场表现十分强劲。”“苹果的供应链开始复苏，但由于关键零部件短缺，苹果在第四季度仍被迫减产，无法生产足够的iPhone来满足需求。”</p></body></html>","source":"XLCJ","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>外媒头条：一次加息50个基点！市场预期越发激进</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n外媒头条：一次加息50个基点！市场预期越发激进\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-19 05:37 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2022-01-19/doc-ikyamrmz6036284.shtml><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>全球财经媒体昨夜今晨共同关注的头条新闻主要有：1、货币市场预计美联储或一次升息50基点 将是2020年以来最大动作2、微软发起其史上最大规模收购 以近690亿美元收购动视暴雪3、贝莱德CEO：美联储“激进”立场或导致收益率曲线趋平4、原油飙升至2014年以来高点 拜登政府称正继续与产油国合作5、研究显示omicron感染浪潮可能降低疫情未来的严重程度6、2021年苹果手机占全球智能手机出货量22%...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2022-01-19/doc-ikyamrmz6036284.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/02a85629f2a809e4eabd8677140a5f70","relate_stocks":{"BK4559":"巴菲特持仓",".IXIC":"NASDAQ Composite","BK4550":"红杉资本持仓","BK4534":"瑞士信贷持仓",".SPX":"S&P 500 Index",".DJI":"道琼斯","BK4504":"桥水持仓"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2022-01-19/doc-ikyamrmz6036284.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204841800","content_text":"全球财经媒体昨夜今晨共同关注的头条新闻主要有：1、货币市场预计美联储或一次升息50基点 将是2020年以来最大动作2、微软发起其史上最大规模收购 以近690亿美元收购动视暴雪3、贝莱德CEO：美联储“激进”立场或导致收益率曲线趋平4、原油飙升至2014年以来高点 拜登政府称正继续与产油国合作5、研究显示omicron感染浪潮可能降低疫情未来的严重程度6、2021年苹果手机占全球智能手机出货量22% 位居第一货币市场预计美联储或一次升息50基点 将是2020年以来最大动作货币市场价格显示，越来越多投资者预期美联储可能逾二十年来首次大规模提高借贷成本。虽然加息25个基点仍是最有可能的情形，但掉期市场现在预计3月底前加息幅度将超过25个基点。鉴于本月政策会议预计不会有任何行动，这表明交易员至少正在考虑3月加息50个基点的可能性。自2000年5月以来， 美联储还从没有一口气加息这么多过。近日来围绕美联储更大幅加息的猜测升温可能加剧了周二美国国债跌势。 摩根大通首席执行官杰米·戴蒙上周警告美联储收紧政策可能不会像一些人预期的那样“和风细雨”，亿万富翁投资者Bill Ackman表示美联储应该在3月加息50个基点，以重建公信力。CFTC最新持仓数据显示，对冲基金将净欧洲美元空头头寸提高至2018年12月以来最大水平，投机者对10年期国债期货的看空程度也达到2020年2月以来最高。微软发起其史上最大规模收购 以近690亿美元收购动视暴雪微软宣布以687亿美元收购动视暴雪，促成视频游戏领域的两大巨头强强联合。作为微软有史以来进行的最大一笔收购，该交易对这家美国最大游戏发行商之一的收购价为每股95美元现金。微软称，动视暴雪首席执行官Bobby Kotick将继续担任当前职位。交易完成后，动视暴雪业务将汇报给微软游戏部门负责人Phil Spencer。交易完成后，微软将成为按营收计算的全球第三大游戏公司，仅次于腾讯和索尼。将动视暴雪热门游戏收入囊中，将有助于微软扩大其Xbox游戏机内容，提高对索尼PlayStation的竞争力。动视暴雪与Xbox的合作由来已久。这家发行商最大一款游戏《使命召唤》的成功，很大程度上是得益于微软创新性的在线平台Xbox Live，该平台允许玩家联机进行多人对战。动视暴雪大多数游戏都在Xbox游戏机上发布。贝莱德CEO：美联储“激进”立场或导致收益率曲线趋平全球最大资产管理公司贝莱德CEO Larry Fink表示，美联储快速调整货币政策以遏制通胀可能会导致美国国债收益率曲线趋于平缓。“我认为收益率曲线将会变平，如果美联储非常激进，我甚至可以看到一条负的收益率曲线，”Fink周二表示。收益率曲线的形状揭示了投资者对美国经济增长和货币政策的预期。美联储计划早于预期加息的鹰派立场推高了短期利率，使曲线变平。分析师通常认为，短期美国国债收益率与较长期美债收益率之差缩小（即收益率曲线趋平），是对经济增长和货币政策不确定性的担忧迹象。负的收益率曲线或曲线倒挂通常预示着经济衰退。“收益率曲线的形状将成为决定经济的关键问题，”Fink说。原油飙升至2014年以来高点 拜登政府称正继续与产油国合作油价升至七年高点之际，白宫称拜登政府正在与产油国合作，将确保供应达到足以满足需求的水平。美国国家安全委员会发言人Emily Horne周二在一份声明中表示，白宫计划继续在全球经济增长的背景下监控能源价格，必要时会与OPEC+国家举行磋商。Horne称，“我们会继续与产油国和消费国合作，这些措施已经对价格产生了实际影响，我们仍然保留可解决能源价格问题的工具” 。汽油价格上涨一直是导致拜登任期内通胀飙升的主要因素，白宫千方百计降低汽油成本。油价上涨正在损害拜登的支持率，民主党在11月中期选举中保住两院多数党地位的难度加大。研究显示omicron感染浪潮可能降低疫情未来的严重程度南非的研究人员表示，虽然omicron变种病毒引发一轮强烈的新冠疫情浪潮，但却可能会加速大流行病所造成各种干扰的终结，因为感染omicron的症状似乎较轻，并能提供针对德尔塔变种病毒的保护。南非一个实验室将去年11月和12月感染omicron的23人作为样本进行的研究显示，虽然先前感染了德尔塔毒株的人可以感染omicron，但感染omicron株的人不会再感染德尔塔。尽管omicron的感染力明显高于德尔塔，但包括南非在内的一些国家的医院和死亡率数据似乎表明，它导致的疾病严重程度较低。南非是最早出现omicron感染浪潮的国家。南非卫生研究所Alex Sigal等人的这项研究显示，omicron可以取代德尔塔毒株。“这种取代的影响将取决于omicron的致病性是否确实低于德尔塔，”研究人员说。 “如果的确如此，那么Covid-19重症的发生率将降低，疫情对个人和社会的破坏性将会减弱。”2021年苹果手机占全球智能手机出货量22% 位居第一数据研究机构Canalys发布的最新报告显示，得益于iPhone 13的成功，苹果手机在2021年占全球智能手机出货量的22%，坐上全球智能手机市场的头把交椅，三星以20%的市场份额紧随其后。此外，小米以12%排名第三，OPPO以9%排名第四，vivo以8%排名前五。报告显示，截至2021年底，苹果手机占全球智能手机出货量的22%。Canalys指出，苹果上一次在智能手机市场排名第一是在2020年第四季度。Canalys分析师Sanyam Chaurasia在一份声明中表示：“苹果iPhone新旗舰机在中国市场表现十分强劲。”“苹果的供应链开始复苏，但由于关键零部件短缺，苹果在第四季度仍被迫减产，无法生产足够的iPhone来满足需求。”","news_type":1,"symbols_score_info":{".DJI":1,".IXIC":1,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":4209,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696638036,"gmtCreate":1640677949442,"gmtModify":1640677949520,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582126034262927","authorIdStr":"3582126034262927"},"themes":[],"htmlText":"Ok,goood","listText":"Ok,goood","text":"Ok,goood","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696638036","isVote":1,"tweetType":1,"viewCount":2014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696076550,"gmtCreate":1640587154486,"gmtModify":1640587154568,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582126034262927","authorIdStr":"3582126034262927"},"themes":[],"htmlText":"Ok, great idea","listText":"Ok, great idea","text":"Ok, great idea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696076550","isVote":1,"tweetType":1,"viewCount":2587,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698712448,"gmtCreate":1640541251767,"gmtModify":1640541251767,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582126034262927","authorIdStr":"3582126034262927"},"themes":[],"htmlText":"Okokok☺️☺️☺️","listText":"Okokok☺️☺️☺️","text":"Okokok☺️☺️☺️","images":[{"img":"https://static.tigerbbs.com/a253a16a74a2b4e30af15fc0fad7fd1b","width":"1599","height":"899"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698712448","isVote":1,"tweetType":1,"viewCount":2005,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":698424747,"gmtCreate":1640503796905,"gmtModify":1640503796987,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582126034262927","authorIdStr":"3582126034262927"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698424747","repostId":"2193781141","repostType":4,"isVote":1,"tweetType":1,"viewCount":2269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698214842,"gmtCreate":1640404859740,"gmtModify":1640404859857,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582126034262927","authorIdStr":"3582126034262927"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698214842","repostId":"2193720178","repostType":2,"isVote":1,"tweetType":1,"viewCount":2251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698820820,"gmtCreate":1640343733999,"gmtModify":1640344031317,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582126034262927","authorIdStr":"3582126034262927"},"themes":[],"htmlText":"Okokok good idea","listText":"Okokok good idea","text":"Okokok good idea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698820820","isVote":1,"tweetType":1,"viewCount":2193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698867692,"gmtCreate":1640343626830,"gmtModify":1640343654207,"author":{"id":"3582126034262927","authorId":"3582126034262927","name":"TAN PS","avatar":"https://static.tigerbbs.com/5a0d84dc68e395bfc24b888753e86fdb","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582126034262927","authorIdStr":"3582126034262927"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698867692","repostId":"2193414198","repostType":2,"isVote":1,"tweetType":1,"viewCount":1696,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}